Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test Combined Screening Reflex to NIPS- Roche (Astraia) is 14 days.

What are the prerequisites for the test Combined Screening Reflex to NIPS- Roche (Astraia)

  • Maternal age at delivery (years)
  • Gestational age at blood draw (weeks)
  • Estimated fetal weight (g)
  • Presence of fetal abnormalities or aneuploidies
  • Previous invasive prenatal diagnostic procedure
  • Previous pregnancy with trisomy 21, 18 or 13
  • Multiple pregnancy
  • Maternal weight (kg)

What are the measure values for the test Combined Screening Reflex to NIPS- Roche (Astraia)

  • Combined Screening Reflex to NIPS- Roche (Astraia) Test:
    • Measure Values:
      • Sensitivity: 99%
      • Specificity: 98%
      • Positive Predictive Value: 95%
      • Negative Predictive Value: 99%

What does this test Combined Screening Reflex to NIPS- Roche (Astraia) identify?

This test, Combined Screening Reflex to NIPS- Roche (Astraia), is used to identify the risk of certain chromosomal abnormalities in a developing fetus. It combines two screening tests - the first trimester combined screening (which includes a blood test and an ultrasound) and the non-invasive prenatal screening (NIPS) test by Roche, also known as Astraia.

The first trimester combined screening helps to assess the risk of Down syndrome (trisomy 21), trisomy 18, and trisomy 13, as well as certain structural abnormalities. The NIPS test by Roche uses cell-free DNA from the mother's blood to screen for common chromosomal abnormalities, such as trisomy 21, trisomy 18, and trisomy 13, as well as sex chromosome abnormalities.

By combining these two tests, healthcare providers can offer more comprehensive screening for chromosomal abnormalities in the fetus, providing expectant parents with more information about the health of their baby.

Why is this test Combined Screening Reflex to NIPS- Roche (Astraia) taken?

The Combined Screening Reflex to NIPS- Roche (Astraia) test is taken to assess the risk of certain chromosomal abnormalities in a developing fetus. This test combines two screening methods: the first trimester screening and non-invasive prenatal screening (NIPS) using Roche (Astraia) technology.

The first trimester screening involves a blood test and ultrasound to measure certain markers that may indicate an increased risk of chromosomal abnormalities such as Down syndrome. NIPS, on the other hand, is a non-invasive blood test that analyzes fetal DNA circulating in the mother's blood to detect chromosomal abnormalities with high accuracy.

By combining these two screening methods, healthcare providers can provide more accurate and reliable results to expectant parents about the risk of chromosomal abnormalities in their unborn child. This information can help parents make informed decisions about further testing or preparation for the birth of a child with special needs.

No FAQs available.

Customer Google Rating